Tags

Type your tag names separated by a space and hit enter

Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
Clin Exp Nephrol. 2014 Jun; 18(3):507-14.CE

Abstract

BACKGROUND

Secondary hyperparathyroidism (SHPT) is common in end-stage renal disease. Our primary objective was to evaluate the efficacy of oral paricalcitol versus oral calcitriol on serum intact parathyroid hormone (iPTH) and mineral bone parameters in continuous ambulatory peritoneal dialysis (CAPD) patients with SHPT. The secondary objective was to analyze highly sensitive C-reactive protein (hsCRP) and peritoneal membrane function in both groups.

METHODS

This was a prospective randomized control trial. CAPD patients with SHPT were randomized to paricalcitol or calcitriol for 15 weeks. Serum intact iPTH, calcium, phosphate and alkaline phosphatase (ALP) were measured at baseline and every 3 weeks. Serum hsCRP and peritoneal membrane functions were measured at baseline and at week 15.

RESULTS

A total of 26 patients were enrolled and randomized-12 to paricalcitol and 14 to calcitriol. Serum iPTH reduced significantly in both groups and there was no difference in the incidence of ≥50 % reduction of iPTH between both groups. There was a significant increase in serum calcium in both groups but there were no differences in serum phosphorus across the visits. The incidence of hypercalcemia was the same in both groups. Serum calcium-phosphorus (Ca × P) product increased in the paricalcitol group but decreased in the calcitriol group. Serum ALP decreased significantly in both groups. There were also no differences in pre- and post-treatment serum hsCRP and peritoneal function test (PFT) in both groups.

CONCLUSION

Both oral paricalcitol and calcitriol were equally efficacious in reducing serum iPTH but were associated with significantly higher serum calcium. Serum Ca × P product increased in the paricalcitol group and decreased in the calcitriol group. Serum hsCRP level and PFT were not affected by either treatment. A larger randomized controlled trial is indicated to confirm these initial findings.

Authors+Show Affiliations

Nephrology Unit, Department of Medicine, University Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Cheras, Kuala Lumpur, Malaysia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23903802

Citation

Jamaluddin, Ema J., et al. "Oral Paricalcitol Versus Oral Calcitriol in Continuous Ambulatory Peritoneal Dialysis Patients With Secondary Hyperparathyroidism." Clinical and Experimental Nephrology, vol. 18, no. 3, 2014, pp. 507-14.
Jamaluddin EJ, Gafor AH, Yean LC, et al. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol. 2014;18(3):507-14.
Jamaluddin, E. J., Gafor, A. H., Yean, L. C., Cader, R., Mohd, R., Kong, N. C., & Shah, S. A. (2014). Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. Clinical and Experimental Nephrology, 18(3), 507-14. https://doi.org/10.1007/s10157-013-0844-2
Jamaluddin EJ, et al. Oral Paricalcitol Versus Oral Calcitriol in Continuous Ambulatory Peritoneal Dialysis Patients With Secondary Hyperparathyroidism. Clin Exp Nephrol. 2014;18(3):507-14. PubMed PMID: 23903802.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. AU - Jamaluddin,Ema J, AU - Gafor,Abdul Halim Abdul, AU - Yean,Loo Chee, AU - Cader,Rizna, AU - Mohd,Rozita, AU - Kong,Norella C T, AU - Shah,Shamsul Azhar, Y1 - 2013/08/02/ PY - 2012/10/04/received PY - 2013/07/16/accepted PY - 2013/8/2/entrez PY - 2013/8/2/pubmed PY - 2015/7/29/medline SP - 507 EP - 14 JF - Clinical and experimental nephrology JO - Clin Exp Nephrol VL - 18 IS - 3 N2 - BACKGROUND: Secondary hyperparathyroidism (SHPT) is common in end-stage renal disease. Our primary objective was to evaluate the efficacy of oral paricalcitol versus oral calcitriol on serum intact parathyroid hormone (iPTH) and mineral bone parameters in continuous ambulatory peritoneal dialysis (CAPD) patients with SHPT. The secondary objective was to analyze highly sensitive C-reactive protein (hsCRP) and peritoneal membrane function in both groups. METHODS: This was a prospective randomized control trial. CAPD patients with SHPT were randomized to paricalcitol or calcitriol for 15 weeks. Serum intact iPTH, calcium, phosphate and alkaline phosphatase (ALP) were measured at baseline and every 3 weeks. Serum hsCRP and peritoneal membrane functions were measured at baseline and at week 15. RESULTS: A total of 26 patients were enrolled and randomized-12 to paricalcitol and 14 to calcitriol. Serum iPTH reduced significantly in both groups and there was no difference in the incidence of ≥50 % reduction of iPTH between both groups. There was a significant increase in serum calcium in both groups but there were no differences in serum phosphorus across the visits. The incidence of hypercalcemia was the same in both groups. Serum calcium-phosphorus (Ca × P) product increased in the paricalcitol group but decreased in the calcitriol group. Serum ALP decreased significantly in both groups. There were also no differences in pre- and post-treatment serum hsCRP and peritoneal function test (PFT) in both groups. CONCLUSION: Both oral paricalcitol and calcitriol were equally efficacious in reducing serum iPTH but were associated with significantly higher serum calcium. Serum Ca × P product increased in the paricalcitol group and decreased in the calcitriol group. Serum hsCRP level and PFT were not affected by either treatment. A larger randomized controlled trial is indicated to confirm these initial findings. SN - 1437-7799 UR - https://www.unboundmedicine.com/medline/citation/23903802/Oral_paricalcitol_versus_oral_calcitriol_in_continuous_ambulatory_peritoneal_dialysis_patients_with_secondary_hyperparathyroidism_ L2 - https://dx.doi.org/10.1007/s10157-013-0844-2 DB - PRIME DP - Unbound Medicine ER -